Pfizer Inc. CEO Ian Read said Thursday that continuing expirations of drug patents through 2015 will restrain revenue growth, but the world's largest drugmaker is trying to offset that with launches of several medicines and research to create new ones.
Read told shareholders at the company's annual meeting that Pfizer launched clot- and stroke-preventing pill Eliquis this year and has recently launched rheumatoid arthritis pill Xeljanz and five cancer medicines.
Read noted top products including Enbrel for psoriasis and rheumatoid arthritis and pain relievers Celebrex and Lyrica also helped, posting strong volume growth in 2012. Meanwhile, sales of consumer health products such as Advil pain reliever and Centrum vitamins climbed 8 percent last year.
Executives of the New York-based drugmaker said it's now focusing more of its research on less-common disorders such as sickle cell anemia and cystic fibrosis, and on vaccines against deadly diseases, including an infection often acquired in hospitals, C. difficile. Other targets include a rare form of dementia and Huntington's disease, a genetic neurodegenerative disorder that causes cognitive decline, psychiatric problems and decreased muscle coordination.
"We would expect to see many of these products advancing into clinical trials in the second half of this decade," Read said at the annual meeting, at a hotel in Short Hills in northern New Jersey.
Pfizer's revenue already is suffering from the November 2011 expiration of the patent on cholesterol-lowering drug Lipitor. It had reigned as the world's top-selling drug for nearly a decade and still brought Pfizer more than $10 billion a year when generic competition arrived.
That loss is compounded by slowing growth in developed countries. Read noted that health programs in Europe and the U.S. continue trying to hold down what they pay for medicines.
Like other pharmaceutical companies, Pfizer is trying to maintain its bottom line through continued job eliminations and cuts to other expenses. Pfizer reduced expenses by nearly $4 billion in 2012 compared to 2011, according to Read.
Pfizer also continues to try to boost sales in emerging markets and saw sales jump about 30 percent last year in China's enormous market, where Pfizer has launched a joint venture to sell patented drugs both in China and other countries.
Read noted that last year the company launched a joint venture in China called Hisun-Pfizer Pharmaceuticals to sell off-patent medicines there and in other countries. In November, Pfizer bought NextWave Pharmaceuticals Inc., which makes the recently approved Quillivant XR, an extended-released liquid medicine for attention deficit disorder.
Pfizer also raised nearly $12 billion last year by selling its nutritional business to Nestle SA and another $6 billion through a partial initial public offering of about 20 percent of its animal health business, now called Zoetis.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
About 130 Indiana National Guard Soldiers returned home Wednesday to friends and family after nearly a year in Afghanistan.
Federal investigators are looking into multiple cases where counterfeiters have floated fake $100 bills. According to police reports, Indianapolis Metropolitan Police Department arrested three people for printing off the fake bills.
Update: According to the Lafayette Police Department, Lafayette area schools have been checked and the threat has been deemed not credible and lockdown lifted.